In cancers, the activity of receptors—in particular, EGFR and HER2—is increased by gene amplification, mutation of the kinase or extracellular domain, and aberrant splicing contributing to several hallmarks of cancer [123,124]. This evidence concerns the gene ERBB2 and cancer.